Bose et al., 2019 - Google Patents
Immune pharmacodynamic responses of the novel cancer immunotherapeutic imprime PGG in healthy volunteersBose et al., 2019
- Document ID
- 9894779791331052187
- Author
- Bose N
- Ottoson N
- Qiu X
- Harrison B
- Lowe J
- Uhlik M
- Rathmann B
- Kangas T
- Jordan L
- Ertelt K
- Jonas A
- Walsh R
- Chan A
- Fulton R
- Leonardo S
- Fraser K
- Gorden K
- Matson M
- Graff J
- Huhn R
- Publication year
- Publication venue
- The Journal of Immunology
External Links
Snippet
Imprime PGG (Imprime) is an iv administered, yeast β-1, 3/1, 6 glucan in clinical development with checkpoint inhibitors. Imprime-mediated innate immune activation requires immune complex formation with naturally occurring IgG anti-β glucan Abs (ABA) …
- 230000004044 response 0 title abstract description 46
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ribas et al. | Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma | |
| Kaplon et al. | Antibodies to watch in 2019 | |
| Hoves et al. | Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity | |
| Bridge et al. | Cytokines, chemokines, and other biomarkers of response for checkpoint inhibitor therapy in skin cancer | |
| Han et al. | Role of CXCR3 signaling in response to anti-PD-1 therapy | |
| Rommer et al. | Monoclonal antibodies in treatment of multiple sclerosis | |
| Bröske et al. | Pharmacodynamics and molecular correlates of response to glofitamab in relapsed/refractory non-Hodgkin lymphoma | |
| Meghani et al. | First-in-human intravesical delivery of pembrolizumab identifies immune activation in bladder cancer unresponsive to Bacillus Calmette-Guérin | |
| Bose et al. | Immune pharmacodynamic responses of the novel cancer immunotherapeutic imprime PGG in healthy volunteers | |
| Cohen et al. | Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment-naïve head and neck squamous cell carcinoma: results from a multicenter, phase II trial | |
| AU2019371243A1 (en) | Bispecific CD123 x CD3 diabodies for the treatment of hematologic malignancies | |
| Rodríguez et al. | The anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial | |
| CN114174538A (en) | Multiple tumor gene signatures suitable for immunooncology therapy | |
| Strauss et al. | First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma | |
| Lambert et al. | Association of baseline and pharmacodynamic biomarkers with outcomes in patients treated with the PD-1 inhibitor budigalimab | |
| Shree et al. | A clinical trial of therapeutic vaccination in lymphoma with serial tumor sampling and single-cell analysis | |
| US20220339249A1 (en) | Composite biomarker for cancer therapy | |
| KR20210146348A (en) | how to treat a tumor | |
| WO2022150582A1 (en) | T cell therapy | |
| US20220233691A1 (en) | Cell localization signature and combination therapy | |
| WO2020243568A1 (en) | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy | |
| Ma et al. | Preclinical characterization and phase 1 results of ADG106 in patients with advanced solid tumors and non-Hodgkin’s lymphoma | |
| Quiroga et al. | An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer | |
| US20220259669A1 (en) | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy | |
| Noman et al. | Targeting the Atypical Chemokine Receptor 2 (ACKR2) improves the benefit of anti-PD-1 immunotherapy in melanoma |